Chris Kresser: With the botanicals, even though Apex has broken them down into antifungal and antiparasitic and antibacterial, most botanicals have activity against more than one microbe. That’s one of the things that differentiates them from pharmaceuticals. What I would say is it may be true that if you remove HPLR, it might have less effect on the beneficial bacterial, but what I would say overall is that in patients with insufficiency dysbiosis, just generally limiting the length of antimicrobial treatment is probably the best idea. But this patient also has parasites and yeast, and without knowing which parasites they have, sometimes those can be difficult to treat, and sometimes it might require antiparasitic drugs. One possible advantage to antiparasitic drugs is that many of them don’t affect the beneficial bacteria to the extent that antibiotics do and possibly even long-term use of antimicrobial botanicals, although there’s less research on that. So I would still do the two-phase approach where you focus on reducing the pathogenic load in the first step and then rebuilding in the second step.